GREY:KONEF - Post by User
Post by
maysilverstoneon Sep 13, 2021 1:24pm
73 Views
Post# 33849170
Ketamine One Digital Therapeutic initiatives
Ketamine One Digital Therapeutic initiatives I recently read this article on psychedelic finance where atai Life Sciences announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD).
The integration of Introspect's digital therapeutic approach working to improve the safety and effectiveness of many mental health treatments made me think back to Ketamine One's digital therapeutic initiatives:
- Agreement with Cognetivity, a tech company, for their Integrated Cognitive Assessment to be deployed in Ketamine One's clinics across North America. ICA is a cognitive testing platform that enables the long-term monitoring of cognitive performance in patients with TRD or PTSD.
- Working together to develop next-generation mental health assessment tools, and Ketamine One believes that Cognetivity can offer a unique and technologically advanced assessment tool that can help standardize in clinic procedures and offer a powerful analytical element to their digital therapeutic platform.
- Digital therapeutics and wearable's that track patient vitals before, during and after psychedelic-assisted therapies.
With the global digital therapeutics market expected to reach USD $13.8B by 2027, growing at a CAGR of 20.5%, I'm looking forward to see what the future holds for $MEDI and their digital therapeutic initiatives.